

1642

LUD 561 CIP - NDH (10006411)

BY HAND DELIVERY

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to the U.S. Patent and Trademark Office by hand-delivery on the date shown below.

Date: 9/22/03

Signature:

Fani Malikouzakis

FULBRIGHT & JAWORSKI LLP

RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : JAGER, et al.  
Serial No. : 09/602,362  
Filed : June 22, 2000  
For : ISOLATED NUCLEIC ACID MOLECULES ENCODING  
CANCER ASSOCIATED ANTIGENS, THE ANTIGENS PER SE,  
AND USES THEREOF  
Group Art Unit : 1642  
Examiner : Gary Nickol

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


LETTER RE SEQUENCES

S I R:

Responsive to the e-mail sent by the Examiner on September 22, 2003, transmitted are copies of the papers sent to the USPTO on May 5, 2003, and received by the USPTO on May 12, 2003. Also submitted is a replacement diskette.


Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

  
Norman D. Hanson, Esq.  
Registration No. 30,946

**DISK TO STIC**

DATE:



666 Fifth Avenue  
New York, New York 10103-3198  
Telephone: 212-318-3168  
Telecopier: 212-318-3400


VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via First Class Mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on May 5, 2003.

Fulbright & Jaworski L.L.P.

Laurie Olds  
Laurie Olds

*Duplicate*  
LUD 5615.1 (10006411) - NDH



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	: Jager, et al.
Serial No	: 09/602,362
Filed	: June 22, 2000
For	: ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER ASSOCIATED ANTIGENS
Art Unit	: 1642
Examiner	: G. B. Nickol

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

May 5, 2003

**LETTER RE**  
**SEQUENCES**

Responsive to the action of April 24, 2003, please replace the paper copy and computer readable forms of sequence information with the attached.

The undersigned hereby declares that, to the best, of his knowledge, the paper copy and computer readable form of sequence information are identical to each other and to information set forth in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By

Norman D. Hanson  
Norman D. Hanson  
Reg. No. 30,946



RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

NDH

Atty Docket No.: LUD 5615.1

Reference:  
Inventor

Jager, et al.

Application 09/602,362

Filing Date: June 22, 2000

Title:

ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER  
ASSOCIATED ANTIGENS

Documents Filed:

Response to Sequence Defect Notice

Paper Copy and CRF of Sequence Listing

Check for \$55.00 one month extension of time

Request for one month extension of time

Via: First Class Mail  
Sender's LO



Date: 05/05/03



NDH

Atty Docket No.: LUD 5615.1

**Reference:**

**Inventor**

Jager, et al.

**Application**

09/602,362

**Filing Date:** June 22, 2000

**Title:**

ISOLATED NUCLEIC ACID MOLECULES ENCODING CANCER  
ASSOCIATED ANTIGENS

**Documents Filed:**

Response to Sequence Defect Notice

Paper Copy and CRF of Sequence Listing

Check for \$55.00 one month extension of time

Request for one month extension of time

**RECEIVED**  
SEP 26 2003  
TECH CENTER 1600/2900

**Via: First Class Mail**

**Sender's**


LO

**Date:** 05/05/03

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 
- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: There was no CRF on the disk.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**